A double-blind, placebo controlled, pilot study to assess the safety and preliminary efficacy of PSD506 in treatment-naive or previously treated (washed out) patients with benign prostatic obstruction and lower urinary tract symptoms
Latest Information Update: 25 Nov 2019
At a glance
- Drugs PSD 506 (Primary)
- Indications Benign prostatic hyperplasia; Lower urinary tract symptoms
- Focus Adverse reactions; Therapeutic Use
- Sponsors Plethora Solutions
- 09 Jul 2007 New trial record.